We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nemaura Medical Inc | NASDAQ:NMRD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1053 | 0.11 | 0.13 | 0 | 01:00:00 |
ABOUT THIS PROSPECTUS SUPPLEMENT
|
S-1
|
|||
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
S-2
|
|||
PROSPECTUS SUPPLEMENT SUMMARY
|
S-3
|
|||
THE OFFERING
|
S-15
|
|||
RISK FACTORS
|
S-16
|
|||
USE OF PROCEEDS
|
S-18
|
|||
CAPITALIZATION
|
S-19
|
|||
DILUTION
|
S-20
|
|||
MANAGEMENT
|
S-21
|
|||
DESCRIPTION OF COMMON STOCK
|
S-22
|
|||
PLAN OF DISTRIBUTION
|
S-23
|
|||
INCORPORATION BY REFERENCE OF CERTAIN DOCUMENTS
|
S-24
|
|||
WHERE YOU CAN FIND MORE INFORMATION
|
S-24
|
|||
LEGAL MATTERS
|
S-24
|
|||
EXPERTS
|
S-24
|
ABOUT THIS PROSPECTUS
|
1
|
|||
PROSPECTUS SUMMARY
|
2
|
|||
RISK FACTORS
|
4
|
|||
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
5
|
|||
USE OF PROCEEDS
|
6
|
|||
RATIO OF EARNINGS TO FIXED CHARGES
|
7
|
|||
DESCRIPTIONS OF THE SECURITIES WE MAY OFFER
|
8
|
|||
PLAN OF DISTRIBUTION
|
19
|
|||
LEGAL MATTERS
|
21
|
|||
EXPERTS
|
21
|
|||
LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
|
21
|
|||
WHERE YOU CAN FIND MORE INFORMATION
|
21
|
|||
INFORMATION INCORPORATED BY REFERENCE
|
21
|
•
|
any statements of the plans, strategies and objectives of management for future operations;
|
•
|
any statements concerning proposed new products, services or developments;
|
•
|
any statements regarding future economic conditions or performance;
|
•
|
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
|
•
|
our estimates regarding the sufficiency of our cash resources and our need for additional funding; and
|
•
|
our intended use of the net proceeds from the offerings of shares of common stock under this prospectus supplement.
|
● |
web-server accessible by physicians and diabetes professionals to track the condition remotely, thereby reducing healthcare costs and managing the condition more effectively;
|
● |
complete virtual doctor that monitors a person's vital signs and transmits results via the web; and
|
● |
other patches using the BEAT technology platform to measure alternative analytes, including lactate, uric acid, lithium and drugs. This would be a step-change in the monitoring of conditions, particularly in the hospital setting. Lactate monitoring is currently used to determine the relative fitness of professional athletes.
|
Milestone
|
Target Start Date
|
Target Completion Date
|
Completion of clinical studies in Type 1 and Type 2 diabetic subjects to define final device claims and for submission for CE Mark approval with final device claims.
|
Completed
|
|
Scale up of commercial sensor/patch manufacturing
(Scale up means we have started looking at larger scales - sufficient for product launch in the UK. It refers to the manufacturing process for sensors.)
|
January 2017
|
Initial Phase Completed |
Scale up of device (transmitter) manufacturing
|
January 2017
|
Ongoing
|
CE Mark for body worn transmitter device
|
April 2018
|
December 2018
|
Commercial launch in the UK, followed by major territories in Europe
|
Q4 2018
|
Staggered launch
|
Commence clinical trial to support U.S. PMA
|
To Be Determined
|
To Be Determined
|
● |
Commercialize sugarBEAT in the United Kingdom and Republic of Ireland with Dallas Burston Pharma (Jersey) Limited, with whom we have an exclusive marketing rights agreement for these two countries.
We have also signed a full commercial agreement with Dallas Burston Ethitronix (Europe) Limited in May 2018 for all other European territories as part of an equal joint venture agreement. The joint venture intends to seek sub-license rights opportunities to one or more leading companies in the diabetes monitoring space, to leverage their network, infrastructure and resources.
|
● |
Establish licensing or joint venture agreements with other parties to market sugarBEAT in other geographies
. We are in detailed discussions and negotiations with several other parties worldwide for licensing or joint venture agreements for the sale of the sugarBEAT device.
|
● |
Conduct a clinical trial in the U.S. to support a PMA for sugarBEAT
. We will conduct further clinical trials to support a PMA for FDA approval to market sugarBEAT in the U.S, timings for which are yet to be confirmed.
|
● |
Expand the indications for which the sugarBEAT device may be used.
We believe that the sugarBEAT device may offer significant benefits as compared to those found in the non-acute setting for the monitoring of other diseases. This includes monitoring of lactic acid for performance athletics, and the monitoring of drugs. We intend to complete initial proof of concept in laboratory settings followed by a clinical program for such applications.
|
● |
Expand our product pipeline through our proprietary platform technologies, acquisitions and strategic licensing arrangements.
We intend to leverage our proprietary platform technologies to grow our portfolio of product candidates for the diagnosis of diabetes and other diseases. In addition, we intend to license our product and acquire products and technologies that are consistent with our research and development and business focus and strategies. This may include drug delivery products for the improved management of diabetes, for example improved insulin injector systems, and/or combination drug products for diabetes related drugs.
|
|
|
2013
|
2035
|
|
Adult population
(20-79 years, millions)
|
659
|
669
|
Diabetes (20 – 79 years)
|
||
Regional prevalence (%)
|
8.5
|
10.3
|
Comparative prevalence (%)
|
6.8
|
7.1
|
Number of people with diabetes
(millions)
|
56.3
|
68.9
|
Impaired Glucose Tolerance (20 – 79 years)
|
||
Regional prevalence (%)
|
9.2
|
11.0
|
Comparative prevalence (%)
|
8.1
|
8.9
|
Number of people with IGT (millions)
|
60.6
|
73.7
|
Type 1 diabetes (0 – 14 years)
|
||
Number of children with Type 1
diabetes (thousands)
|
129.4
|
-
|
Number of newly diagnosed cases per year (thousands)
|
20.0
|
-
|
|
|
Countries/Territories
|
Millions
|
Russian Federation
|
10.9
|
Germany
|
7.6
|
Turkey
|
7
|
Spain
|
3.8
|
Italy
|
3.6
|
|
|
FreeStyle Libre™
(1)
|
Platinum G6®
(2)
|
Platinum G5®
(3)
|
Eversense™
(4)
|
SugarBEAT®
|
|
Manufacturer
|
Abbott
|
Dexcom
|
Dexcom
|
Senseonics
|
Nemaura Medical
|
Technology
|
Inserted Sensor
|
Inserted Sensor
|
Inserted Sensor
|
Implanted Sensor
|
Non-invasive Sensor
|
Reliability (Overall MARD)
|
11.4%
|
9.8%
|
9.0%
|
11.4%
|
<14%*
|
Reliability (Clarke Error Grid A+B zone)
|
99%
|
Not available
|
97.0%
|
99.1%
|
>95.0%
|
Patients Studied
|
72
|
324
|
97
|
44
|
>75
|
Patient Days Studies
|
14
|
10
|
9
|
90
|
1 to 4
|
Warm-up Time
|
1 hour
|
2 hours
|
2 hours
|
NA
|
30-60 min
|
Daily Calibration
|
None
|
None
|
2x
|
2x
|
1x
|
Glucose Display Frequency
|
On manual activation of sensor
|
Every 5 min
|
Every 5 min
|
Every 5 min
|
Every 5 min
|
Patch/Senor Life
|
14 days
|
10 days
|
7 days
|
90 days
|
1 day
|
Regulatory Approvals
|
EU
|
US
|
Worldwide
|
EU
|
EU **
|
Basis for reimbursement
|
Finger stick
|
Not available
|
CGM
|
CGM
|
Finger stick
|
Daily Avg. Reimbursement Cost
|
$2.50 (Germany)
|
Not available
|
$9 (US)
|
Not available
|
$2.50***
|
Daily Retail Cost UK (exc. VAT)
|
£3.50 (Patch)
£50 (Reader)
|
Not available
|
£7.30 (Patch)
£475 (Hardware)
|
Not available
|
£2*** (Daily Patch)
£30*** (Transmitter)
|
|
|
IP: Patent (Core Claim), Know-how, Trademark
|
Expiration Date
|
Jurisdictions in which Granted/ Issued
|
Jurisdictions in which
Pending |
Ongoing Royalty or Milestone Payments
|
||
Patent: Cumulative Measurement of an Analyte*.
|
May 20, 2032
|
Australia, France, Germany, Italy, Poland, Spain, Netherlands, UK
|
Brazil, Canada, China, India, Japan, Qatar, United Arab Emirates, U.S.
|
None
|
||
Patent: Patches for Reverse Iontophoresis**
|
July 1, 2029
|
Australia, Germany, France, UK, Italy, Netherlands, Switzerland, China, Hong Kong, Japan.
|
None
|
None
|
||
Know-how: Sensor Formulation
|
N/A
|
Trade Secret
|
N/A
|
N/A
|
||
Trademark: BEAT
|
Renewal due in 2026
|
UK, China, EU, India, Japan
|
Canada
|
N/A
|
||
Trademark: sugarBEAT
|
Renewal due in 2025
|
UK, Australia, Switzerland, China, Egypt, EU, Israel, India, Iran, Japan, North Korea, Morocco, Mexico, Norway, New Zealand, Russia, Singapore, Tunisia, Turkey, USA
|
Canada
|
N/A
|
|
|
|
|
|
|
● |
Class I devices present a low risk and are not life-sustaining or life-supporting. The majority of Class I devices are subject only to "general controls" (e.g., prohibition against adulteration and misbranding, registration and listing, good manufacturing practices, labeling, and adverse event reporting. General controls are baseline requirements that apply to all classes of medical devices.)
|
● |
Class II devices present a moderate risk and are devices for which general controls alone are not sufficient to provide a reasonable assurance of safety and effectiveness. Devices in Class II are subject to both general controls and "special controls" (e.g., special labeling, compliance with performance standards, and post market surveillance. Unless exempted, Class II devices typically require FDA clearance before marketing, through the premarket notification (510(k)) process.)
|
● |
Class III devices present the highest risk. These devices generally are life-sustaining, life-supporting, or for a use that is of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. Class III devices are devices for which general controls, by themselves, are insufficient and for which there is insufficient information to determine that application of special controls would provide a reasonable assurance of safety and effectiveness. Class III devices are subject to general controls and typically require FDA approval of a premarket approval ("PMA") application before marketing.
|
|
|
● |
Establishment registration and device listing requirements;
|
● |
Quality System Regulation ("QSR"), which governs the methods used in, and the facilities and controls used for, the design, manufacture, packaging, labeling, storage, installation, and servicing of finished devices;
|
● |
Labeling requirements, which mandate the inclusion of certain content in device labels and labeling, and generally require the label and package of medical devices to include a unique device identifier ("UDI"), and which also prohibit the promotion of products for uncleared or unapproved, i.e., "off-label," uses;
|
● |
Medical Device Reporting ("MDR") regulation, which requires that manufacturers and importers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and
|
● |
Reports of Corrections and Removals regulation, which requires that manufacturers and importers report to the FDA recalls (i.e., corrections or removals) if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; manufacturers and importers must keep records of recalls that they determine to be not reportable.
|
● |
Untitled letters or warning letters;
|
● |
Fines, injunctions and civil penalties;
|
● |
Recall or seizure of our products;
|
● |
Operating restrictions, partial suspension or total shutdown of production;
|
● |
Refusing our request for 510(k) clearance or premarket approval of new products;
|
● |
Withdrawing 510(k) clearance or premarket approvals that are already granted; and
|
● |
Criminal prosecution.
|
|
|
Common stock offered by us
|
10,101,010 shares of our common stock (at an assumed offering price of $1.98 per share, which was the closing price of our common stock on The NASDAQ Capital Market on October 16, 2018). The actual number of shares to be issued will vary depending on the sales price in this offering.
|
Total Common stock outstanding before
the offering |
205,050,000 shares of common stock.
(1)
|
Common stock to be outstanding after
the offerings |
Up to 215,151,010, assuming the sale of all of the shares of common stock being offered by us (at an assumed offering price of $1.98 per share, which was the closing price of our common stock on The NASDAQ Capital Market on October 16, 2018.). The actual number of shares to be issued will vary depending on the sales price in this offering. .
|
Manner of offering
|
“At the market offering” that may be made from time to time on The NASDAQ Capital Market or other market for our common stock in the U.S. through our agent, Maxim Group, LLC (“Maxim”). Maxim will make all sales using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreeable terms between the sales agent and us. See “Plan of Distribution.”
|
Use of proceeds
|
We will use the net proceeds from this offering for general corporate purposes. See "Use of Proceeds" on page S-18.
|
Risk factors
|
An investment in our shares of common stock is highly speculative and involves a number of risks. You should carefully consider the information contained in the "Risk Factors" section beginning on page S-16 of this prospectus supplement, and elsewhere in this prospectus supplement and the base prospectus, and the information we incorporate by reference, before making your investment decision.
|
NASDAQ Capital Market symbol
|
Our common stock is listed on The NASDAQ Capital Market under the symbol "NMRD."
|
(1) |
The number of shares of common stock to be outstanding after this offering is based on 205,050,000 shares of common stock outstanding on October 16, 2018. The number of shares of common stock excludes 10,000,000 shares of common stock issuable pursuant to the exercise of warrants with a weighted-average exercise price of $0.50 per share.
|
•
|
On an actual basis; and
|
•
|
on an as adjusted basis to give effect to the receipt of estimated net proceeds of $19,250,000 million assuming the sale of 10,101,010 shares of our common stock (at an assumed offering price of $1.98 per share, which was the closing price of our common stock on The NASDAQ Capital Market on October 16, 2018), after deducting the estimated commissions and estimated offering expenses payable by us as described under "Use of Proceeds".
|
As of June 30, 2018(1)
|
||||||||
Actual
|
As
Adjusted |
|||||||
Cash, cash equivalents and short-term investments
|
$
|
4,941,042
|
$ | 24,191,042 | ||||
Stockholders' equity:
|
||||||||
Convertible preferred stock, $0.001 par value, 200,000 shares authorized and -0- issued and outstanding, actual and as adjusted
|
$
|
-
|
$ | - | ||||
Common stock, $0.001 par value, 420,000,000 shares authorized and 205,000,000 shares issued and outstanding, actual, 215,101,010 shares issued and outstanding, as adjusted
|
205,000
|
215,101 | ||||||
Additional paid-in capital
|
12,919,672
|
32,159,571 | ||||||
Accumulated deficit
|
(9,736,239
|
)
|
(9,736,239 | ) | ||||
Accumulated other comprehensive loss
|
(275,234
|
)
|
(275,234 | ) | ||||
Total stockholders' equity
|
3,113,199
|
22,363,199 | ||||||
Total capitalization
|
$
|
5,572,064
|
$ | 24,822,064 | ||||
•
|
10,000,000 shares of common stock issuable upon the exercise of warrants outstanding with a weighted average exercise price of $0.50.
|
Offering price per share
|
$ | 1.98 | ||||||
Net tangible book value per share as of June 30, 2018
|
$ | 0.014 | ||||||
Increase per share attributable to this offering
|
$ | 0.089 | ||||||
As-adjusted net tangible book value per share as of June 30, 2018, after giving effect to this offering
|
$ | 0.103 | ||||||
Dilution per share to new investors participating in this offering
|
$ | 1.877 |
•
|
excludes, as of June 30, 2018, 10,000,000 shares of common stock issuable upon the exercise of warrants outstanding with a weighted average exercise price of $0.50.
|
Name
|
Position
|
Date of Appointment
|
Dewan Fazlul Hoque Chowdhury
|
Chief Executive Officer, President and Director
|
December 24, 2013
|
Bashir Timol
|
Chief Business Officer and Director
|
December 24, 2013
|
Iain Anderson
|
Chief Financial Officer
|
December 12, 2016
|
Thomas Moore (1)
|
Independent Director
|
August 3, 2017
|
Dr. Salim Natha (1)
|
Independent Director
|
July 26, 2017
|
Timothy Johnson (1)
|
Independent Director
|
July 17, 2017
|
● |
our Annual Report on Form 10-K for the fiscal year ended March 31, 2018, filed with the SEC on June 12, 2018;
|
● |
our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the SEC on August 9, 2018;
|
● |
our Current Reports on Form 8-K filed with the SEC on June 27, 2018 and August 6, 2018 and our Current Report on Form 8-K/A filed with the SEC on August 9, 2018;
|
● |
the description of our common stock contained in our Form 8-A12B filed with the SEC on January 19, 2018, including any amendment or report filed for the purpose of updating that description; and
|
● |
all documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, on or after the date of this prospectus supplement and before we stop offering the securities covered by this prospectus supplement and the accompanying base prospectus.
|
PAGE
|
||
ABOUT THIS PROSPECTUS
|
1
|
|
PROSPECTUS SUMMARY
|
2
|
|
RISK FACTORS
|
4
|
|
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
5
|
|
USE OF PROCEEDS
|
6
|
|
RATIO OF EARNINGS TO FIXED CHARGES
|
7
|
|
DESCRIPTIONS OF THE SECURITIES WE MAY OFFER
|
8
|
|
PLAN OF DISTRIBUTION
|
19
|
|
LEGAL MATTERS
|
21
|
|
EXPERTS
|
21
|
|
LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
|
21
|
|
WHERE YOU CAN FIND MORE INFORMATION
|
21
|
|
INFORMATION INCORPORATED BY REFERENCE
|
21
|
PROSPECTUS SUMMARY
This prospectus summary highlights certain information about our company and other information contained elsewhere in this prospectus or in documents incorporated by reference. This summary does not contain all of the information that you should consider before making an investment decision. You should carefully read the entire prospectus, any prospectus supplement, including the section entitled “Risk Factors” and the documents incorporated by reference into this prospectus, before making an investment decision.
THE OFFERING
This prospectus is part of a Registration Statement that we filed with the Securities and Exchange Commission (“
SEC
”) utilizing a shelf registration process. Under this shelf registration process, we may sell any combination of:
|
|||
●
|
common stock;
|
||
●
|
warrants to purchase any of the securities listed above;
|
||
●
|
debt securities, in one or more series; and/or
|
||
●
|
units consisting of one or more of the foregoing.
|
||
in one or more offerings up to a total dollar amount of $87,500,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that specific offering and include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with the additional information described under the heading “Where You Can Find More Information.”
OUR COMPANY
We perform medical device research and manufacturing of a continuous glucose monitoring system (“CGM”), named ‘sugarBEAT.’ The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using unique sensors and the signal is processed and converted to glucose readings using algorithms.
Our primary technology currently consists of
one CGM patch.. The original version of this technology consisted of a device designed for clinical use, which was directly connected to a patch containing a sensor. This device did not have any wireless methods of data transport and all data transport was using a USB cable. The clinical device has been further developed and is available in two variants for all future applications:
|
|||
1.
|
The first of these variants consists of a patch containing a sensor that is applied to the skin. Glucose is extracted from the skin into the patch and the raw data is wirelessly sent to a reader. This reader may be a discrete hand held device specifically produced for the sugarBEAT or it may be a smart phone or smart watch. The reader processes the raw data using algorithms and presents these as glucose readings.
|
||
2.
|
The second variant consists of a watch-like device with a screen, and the device directly connects to the patch containing a sensor (using a wire) and provides direct glucose readings on the screen.
|
||
We have undertaken a CE approval, which is the process to achieve a mandatory conformity marking for the sugarBEAT device to allow it to be legally sold in the European Union. It is a manufacturers' declaration that the product meets the requirements of the applicable European laws. In 2015 we applied to obtain the CE approval for our clinical CGM sugarBEAT system. We were advised on February 25, 2016, that the review process for the CE application had been completed and the sugarBEAT device CE certification is in order for grant.
|
Our manufacturing processes are governed by ISO13485 quality systems, which also governs the sale of medical devices. Our three-year recertification audit was recently completed in February 2016. As a result of the audit, we are required to complete within 60 days, certain observations related to the quality systems, in particular in relation to the recent relocation of our laboratory facilities to a new building on the same site. Upon completion of this exercise we will receive our re-certification for ISO13485/9001. Consequently, the CE approval certificate will not be issued until the re-certification is completed. We expect to complete the recertification no later than April 30, 2016.
Since our first CE mark application for sugarBEAT, we have created a new version of the CGM, variants 1 and 2 described above. The new device iterations are as described above, as variant 1 and 2, with the two key differences being firstly the new devices are smaller than the first device produced, and secondly the new devices have wireless communication means in the form of Bluetooth. It is our intent to submit a new CE mark application by October 31, 2016 for both variants of the new device. Although at this time we may not seek to commercially market and sell the initial sugarBeat device, we may continue to use it in clinics, or sell it as an introductory product in the event there are delays in securing CE approval of the variants for the new version of the CGM.
Our Business Strategy
We intend to lead in the discovery, development and commercialization of innovative and targeted diagnostic medical devices that improve disease monitoring, management and overall patient care. We plan to take the following steps to implement our broad business strategy. Our key commercial strategies post- CE approval of the new variants 1 and 2 of the sugarBEAT will be as follows:
|
|||
●
|
Develop our own specialty sales and marketing teams to market the sugarBEAT device in the European Union
. We intend to develop specialty sales teams with our Joint Venture partner for the EU territory, for the distribution of our product in the European Economic Area, excluding the UK, Channel Islands, the Isle of Man and Republic of Ireland. We have a marketing license agreement for the UK and Republic of Ireland with DB Pharma (Jersey) Ltd. This agreement is in addition to the 50/50 joint venture agreement with the same party for product launch in all territories in the EU outside of the UK, Channel Islands, the Isle of Man and the Republic of Ireland.
|
||
●
|
Develop a Clinical and Commercialization Strategy for Product launch in the USA
. In October 2015 we held a pre-submission meeting with the FDA and expect to hold a second meeting by mid June 2016 with the objective of ensuring that the FDA concurs with our proposed clinical strategy for a
Premarket Approval Application, or PMA
,
submission
. We then intend to conduct studies in the USA and submit our PMA within 18 months of the next FDA pre-submission meeting. In parallel we intend to investigate and develop the optimal product launch and commercialization strategy for the USA.
|
||
●
|
Expand the indications for which the sugarBEAT device may be used.
We believe that the sugarBEAT device may offer other significant benefits other than those found in the non-acute setting for the monitoring of other diseases. This includes monitoring of lactic acid for performance athletics as well as critical care, and the monitoring of drugs for clinical study programs. Initial proof of concept will be completed in laboratory settings followed by a clinical program.
|
||
●
|
Expand our product pipeline through our proprietary platform technologies, acquisitions and strategic licensing arrangements.
We intend to leverage our proprietary platform technologies to grow our portfolio of product candidates for the diagnosis of diabetes and other diseases. In addition we intend to license our product and acquire products and technologies that are consistent with our research and development and business focus and strategies.
|
||
Principal Executive Office
Our principal executive offices were located at Charnwood Building Holywell Park, Ashby Road, Loughborough, Leicestershire, United Kingdom. In August 2015 we relocated to a new-build facility within the same Science Park, The Advanced Technology Centre, Oakwood Drive, Loughborough, Leicestershire, LE113QF, UK. Our website is located at http://www.nemauramedical.com and our telephone number is +44 1509 222912 . Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus or part of any prospectus supplement. Our website address is included in this document as an inactive textual reference only.
|
·
|
shares of our common stock;
|
|
·
|
warrants to purchase any of the securities listed above;
|
|
·
|
debt securities, in one or more series; and/or
|
|
·
|
units consisting of one or more of the foregoing.
|
● |
Our Annual Report on Form 10-K for the fiscal year ended March 31, 2015;
|
● |
Our Quarterly Report on Form 10-Q for the fiscal quarters ended June 30, 2015, September 30, 2015 and December 31, 2015; and
|
● |
Our Current Reports on Form 8-K as filed on December 2, 2015 and March 17, 2015.
|
1 Year Nemaura Medical Chart |
1 Month Nemaura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions